Pfizer's Net Income Surges over 100% in Strong Second Quarter

Pfizer Inc. (NYSE: PFE) reported strong financial results for the second quarter of 2025, with revenues reaching $14.65 billion, marking a 10% increase compared to $13.28 billion in the prior-year quarter. Net income attributable to Pfizer Inc. common shareholders surged to $2.91 billion, a significant rise from $41 million in Q2 2024. This dramatic increase in net income resulted in a year-over-year change greater than 100%. The company reaffirmed its full-year 2025 revenue guidance and raised its Adjusted diluted EPS guidance, demonstrating confidence in its strategic execution.

Commercial Execution Driving Growth

The operational revenue increase was primarily fueled by strong performance across several key products. The Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally saw a 21% operational increase, driven by strong demand and increased patient diagnoses, particularly in the U.S. and developed international markets. Comirnaty's global revenue increased by 95% operationally due to higher net revenues in the U.S. from increased market share and higher contractual deliveries internationally. Paxlovid also contributed significantly with a 71% operational increase, benefiting from higher net prices in the U.S. post-transition from the government agreement.

Further driving growth were Padcev, which saw a 38% operational increase due to increased market share in urothelial cancer, and Eliquis, up 6% operationally due to higher global demand. Abrysvo globally increased by 155% operationally, primarily from higher U.S. revenues for the maternal indication. Lorbrena also experienced substantial growth, up 48% operationally, driven by increased patient share in ALK-positive metastatic non-small cell lung cancer treatment settings in the U.S., China, and other international markets.

Operational Efficiency and Pipeline Progress

Pfizer's financial performance was also bolstered by operational efficiencies. Selling, Informational, and Administrative (SI&A) Expenses decreased by 8% operationally, reflecting focused investments and productivity improvements. Research and Development (R&D) Expenses also saw an 8% operational decrease due to pipeline focus and optimization. The company remains on track to deliver approximately $7.2 billion in overall anticipated net cost savings from previously announced cost improvement initiatives by the end of 2027.

Management Outlook and Strategic Direction

Dr. Albert Bourla, Chairman and CEO of Pfizer, expressed satisfaction with the quarter's focused execution, highlighting progress in advancing the R&D pipeline, enhancing commercial performance, and expanding margins. David Denton, CFO and EVP, noted that the robust revenue and EPS performance underscored the company's commitment to commercial execution and operational efficiency. The raised full-year 2025 Adjusted diluted EPS guidance, now in a range of $2.90 to $3.10, reflects strong year-to-date performance, continued business confidence, favorable foreign exchange impact, ongoing cost improvement initiatives, and an improved effective tax rate. This guidance absorbs the impact of tariffs and potential price changes.